OSLO, Norway, March 19, 2020 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that its Nomination Committee has
nominated Dr Karin Meyer, PhD for
election as a Non-executive Director at the Company's Annual
General Meeting.
The company also notes that Gisela
Schwab, MD, who has served as a Non-executive Director on
the Board of Nordic Nanovector since March
2015 has, due to increased workload, responsibilities and
competing priorities, decided not to stand for re-election at the
upcoming AGM.
Karin Meyer, PhD, has been
nominated for election as a Non-executive Director at the AGM. Dr
Meyer has 25 years of experience in the pharmaceutical/life
sciences area, holding senior management and operational roles in
private and public/non-profit organisations. She is currently Chief
Executive Officer of the Swedish Pharmaceutical Society and
Chairman of the board of two of its subsidiaries -
Läkemedelsakademin i Stockholm AB and SPhS Stockholm Congress AB.
She has spent more than 10 years working in senior roles within
Contract Research Organisations (CROs), including PCG Clinical
Services and Quintiles, and is the former Deputy General Director
of Uppsala University Innovations, with
responsibility for the commercialisation of innovations from the
University, as well as investments, management and exits of
start-up companies.
Dr Meyer is currently a Director on the Boards of Smartfish AS,
Uppsala Monitoring Centre/WHO Collaborating Centre, Kårhuset
Pharmen AB and Chair of the Board of NEPI Foundation (Nätverk för
Läkemedelsepidemiologi). Dr Meyer is a Swedish citizen and resides
in Sweden.
Jan H. Egberts, MD, Chairman of Nordic Nanovector's Board of
Directors, said: "On behalf of the Board, I would like to thank
Gisela for five years of service during which she has made valuable
contributions to the advancement of the Company. I am delighted to
welcome Karin, who brings extensive experience in key areas that
will be invaluable with regards to the future development of the
Company."
The Nomination Committee will continue to consider the most
appropriate Board composition.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains
global marketing rights to Betalutin® and intends to actively
participate in the commercialisation of Betalutin® in the US and
other major markets.
Further information can be found at
www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant
to Sections 4-2 and 5-12 of the Securities Trading Act.
CONTACT:
For further information, please contact:
Jan H. Egberts, Chairman of Nordic Nanovector
Tel: +31-614-672-518
Email: janegberts@aol.com
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer
Hall/David Dible (Citigate Dewe
Rogerson)
Tel: +44-203-926-8535
Email: nordicnanovector@citigatedewerogerson.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa-announces-proposed-board-change,c3064262